|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
McKesson Pays Up for Unhealthy Practices
Posted by: GMI Ratings (IP Logged)
Date: April 27, 2012 03:03PM
While McKesson Corp. (MCK) gets sued for allegations such as inflating prices, the pharmaceutical company's CEO John Hammergren is earning a healthy paycheck.
McKesson agreed to pay more than $190 million to settle claims that it allegedly inflated pricing information for a large number of prescription drugs between 2001 and 2005, the U.S. Attorney's office announced Thursday. As a result, Medicaid overpaid for those drugs. Federal and state governments have already recovered more than $2 billion from drug manufacturers that alleged to have committed similar crimes, the regulator said.
This isn't the first time McKesson has had a run in with its regulators. To name just one recent example, colonoscopy patients allegedly contracted hepatitis in 2008 because the company, along with Baxter International Inc., distributed reusable vials of the anesthetic Propofol on behalf of Teva Pharmaceutical Industries Ltd. A jury ruled in October 2011 that McKesson should be penalized $17.9 million for its involvement in the matter, according to news reports.
These developments took place under the watch of Hammergren, who became president and CEO in 2001. Since taking on the additional responsibility of chairman in 2002, he's earned $46.1 million as of the company's June 2011 proxy filing, well over four times the median for other named executive officers. In 2011 alone, Hammergren raked in $12.5 million. Moreover, he's entitled to a potential payment of nearly $469 million in the event of a termination following a change in control.
Clearly, Hammergren has pulled off some impressive financial results for both himself and McKesson. But profits aren't the only measure of a company's performance, especially in health care, which has a purpose that goes beyond money. Hammergren's record at providing people with the safest, most affordable medicine possible is much less clear, given McKesson's involvement in recent lawsuits.
In part for issues such as its high compensation of executives, GMI gives McKesson an F on its corporate governance overall. Since March 2011 the accounting and governance risk reflected in McKesson's financial statements has ranked third out of four categories at GMI Ratings, which range from conservative to very aggressive.
Stocks Discussed: MCK,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.